Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
VRTX · Nasdaq · Healthcare
Fundamental quality
84
out of 100
Vertex Pharmaceuticals Inc / Ma fits the profile of a quality compounder: it pairs high return on capital (ROE 22.4%) with wide margins (net margin 35.5%) and a business that keeps growing (13.8% a year). On fundamental quality it scores 84 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +13.8%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Vertex Pharmaceuticals is a biotech focused on serious diseases with few treatment options. It almost single-handedly dominates the cystic fibrosis market, whose drugs generate nearly all its revenue, and aims to repeat the formula in areas like pain and kidney disease.
EPS growth: 9.9% · Revenue growth: 13.8%
Net margin: 35.5% · ROE: 22.4% · ROIC: 28.3%
Net debt/EBITDA: -1.12x · FCF: 30.4%
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 6,206 | 2,712 | 2,994 | -5,988 |
| 2021 | 7,574 | 2,342 | 2,409 | -6,795 |
| 2022 | 8,931 | 3,322 | 3,925 | -10,504 |
| 2023 | 9,869 | 3,620 | 3,337 | -10,369 |
| 2024 | 11,020 | -536 | -790 | -4,570 |
| 2025 | 12,001 | 3,953 | 3,194 | -5,085 |
Between 2020 and 2025, revenue went from $6,206M to $12,001M (+93%) and net income went from $2,712M to $3,953M (+46%). Meanwhile, its margins have narrowed (from 44% to 33%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the quarter ended March 31, 2026, versus the quarter ended March 31, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Vertex Pharmaceuticals Inc / Ma cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Vertex Pharmaceuticals Inc / Ma a good company to invest in?
In terms of business quality, Vertex Pharmaceuticals Inc / Ma scores 84 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Vertex Pharmaceuticals Inc / Ma a profitable company?
Very. Vertex Pharmaceuticals Inc / Ma shows a net margin of 35.5% and an ROE of 22.4%, typical of a highly profitable business.
Does Vertex Pharmaceuticals Inc / Ma have a lot of debt?
No. Vertex Pharmaceuticals Inc / Ma has a net cash position: more cash than debt.
Is Vertex Pharmaceuticals Inc / Ma growing?
Its revenue has grown 13.8% annualized in recent years and its earnings per share 9.9%, and without interruption since 2020.
Does Vertex Pharmaceuticals Inc / Ma generate cash?
Yes. It converts about 30.4% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Community Health Systems (CYH) · Hims & Hers Health (HIMS) · Oscar Health (OSCR) · Recursion Pharmaceuticals (RXRX) · Eli Lilly (LLY) · UnitedHealth (UNH) · see more →
The best Healthcare stocks by our model →
Compare Vertex Pharmaceuticals Inc / Ma with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Vertex Pharmaceuticals Inc / Ma's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.